TY - JOUR
T1 - Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage
AU - Deenen, Maarten J.
AU - De Kanter, Clara T M M
AU - Dofferhoff, Anthonius S M
AU - Grintjes-Huisman, Karin J T
AU - Van Der Ven, Andre J A M
AU - Fleuren, Hanneke W H A
AU - Gisolf, Elizabeth H.
AU - Koopmans, Peter P.
AU - Drenth, Joost P H
AU - Burger, David M.
PY - 2015
Y1 - 2015
N2 - Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as
AB - Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as
KW - Coinfection
KW - Hepatitis C
KW - HIV
KW - Ribavirin
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=84947905944&partnerID=8YFLogxK
U2 - 10.1097/FTD.0000000000000226
DO - 10.1097/FTD.0000000000000226
M3 - Article
C2 - 26102531
AN - SCOPUS:84947905944
SN - 0163-4356
VL - 37
SP - 751
EP - 755
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 6
ER -